Analyses of 42,656 clinician learners across 69 CNS-related educational activities reveals clinicians may be unprepared to effectively conduct clinical trials
Charlottesville, VA (PRWeb) November 16, 2022
ArcheMedX, the leading provider of clinician readiness solutions for the life sciences and healthcare industries, today announced the Company’s expanded participation at the CNS Summit taking
2021 was a historic year in the battle to defeat cancer.
More novel cancer treatments became available than ever before with the number of Oncology specific clinical trials also reaching an all-time high, up 56% from 2016 and mostly focused on rare cancer indications.
With global spending on Oncology expected to exceed $300
ArcheMedX, a behavioral science-based learning company providing a smarter way to predict and improve clinical team performance, recently passed a significant data milestone.
PRWeb - Charlottesville, VA March 24, 2022
Today, the Company announced its clinician learning and predictive analytics platform, Ready, has now surpassed more than 25 million essential learning behaviors
The area of clinical research known as CNS (central nervous system conditions) is commonly cited for its complexity and the subjective nature of many assessment tools. CNS clinicians therefore must commit to tackling unique challenges affecting their patients and the research they conduct.
It should be no surprise that the life
Today, ArcheMedX announced that its 2020 industry report, “COVID-19's Impact on Virtual Tech in Clinical Trials, was honored with a prestigious American Marketing Association (AMA) award.
Every year, the AMA honors hundreds of stand-out marketers through awards programs presented by the AMA Foundation, local professional chapters, and academic special interest groups.
Watch on Demand Now!
Clinical trials are more complex than ever.
And 85% of them are delayed.
More screening criteria, more procedures, new vendor systems and tools, and more data. So who bears the burden of all this progress? Sites.
Increased site burden means degraded performance, more delays, and more problems for you. But
CHARLOTTESVILLE, VA Apr. 21, 2021 -- ArcheMedX announced today that ValenzaBio, a biotech focused on developing monoclonal antibody therapeutics for autoimmune and inflammatory indications, has selected Ready, the industry’s leading clinical trial learning and predictive analytics platform, to optimize performance on its upcoming Phase II study.
ValenzaBio is deploying Ready to
ArcheMedX, a leader in behavior-based learning and operational insights for life sciences organizations, announced the release of two new whitepaper companions to its recent report, “COVID-19's Impact on Virtual Tech in Clinical Trials.” These whitepapers, focused on clinical research organizations and clinical trial sponsors, respectively, are intended to be playbooks
ArcheMedX today announced its on-going collaboration with PRA Health Sciences in a highly anticipated joint case study at the 2020 Clinical Trial Innovations Summit.
On Wednesday, 11 November, Kelly Ritch, EVP of Product and Clinical Solutions at ArcheMedX, will join Susan Zakarian, Sr. Manager of PRA Health Sciences to co-present a